Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million

Reuters

2025/11/07

Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million

Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581501208"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581501208\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581501208?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581501208","market":"us","top_or_hot":-1,"title":"Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbfQFvL:1","article_id":"2581501208","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581501208","pubTimestamp":1762462971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $ million, while Adjusted EBITDA was $ million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $ million, compared to $ million last year, with Adjusted EBITDA at $ million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc.","BK4121":"生命科学工具和服务"},"translate_title":"Maravai LifeSciences报告第三季度收入为4160万美元，净亏损为4510万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":0.9},"content_text":"Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    \n\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}